Anzeige
Mehr »
Dienstag, 13.01.2026 - Börsentäglich über 12.000 News
Gold auf Rekordhoch: Eine der spannendsten Gold-Stories 2026 steht ganz am Anfang
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
126 Leser
Artikel bewerten:
(0)

ACell Launches New MatriStem Multilayer Wound Matrix Device

COLUMBIA, Md., Feb. 10, 2014 /PRNewswire/ --ACell, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it has launched the new MatriStem® Multilayer Wound Matrix device for deep, hard-to-heal, full-thickness wounds. The one-to-one (1:1) mesh design of MatriStem Multilayer Wound Matrix is built to accommodate moderate to heavy wound exudate and provides effective contouring functionality in wound application.

MatriStem products are medical devices that maintain and support a healing environment through constructive remodeling. Comprised of naturally-occurring urinary bladder matrix (UBM), MatriStem maintains an intact epithelial basement membrane which is hypothesized to facilitate the body's natural healing potential.

The MatriStem Multilayer Wound Matrix device is easy to prepare, apply and fixate and requires no special handling or storage requirements. MatriStem Multilayer Wound Matrix is appropriate for both acute and chronic wounds.

Jim DeFrancesco, Chief Executive Officer and Board Director, remarked, "ACell has developed MatriStem Multilayer Wound Matrix to address an unmet need in the area of acute and chronic wound care management. The launch of this new product provides a new option for physicians treating patients suffering from deep, hard-to-heal wounds."

MatriStem devices have received multiple 510(k) clearances from the FDA and are indicated for wound management including for pressure ulcers, venous ulcers, diabetic ulcers, surgical wounds and trauma wounds, and the reinforcement of soft tissue where weakness exists in urological, gynecological and gastroenterological anatomy.

ACell, Inc. offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix products to repair and remodel damaged tissues in a broad range of applications. Its patented MatriStem ECM medical devices maintain and support a healing environment through constructive remodeling and are available in particle and sheet forms for the treatment of acute wounds and various surgical procedures. For more information, visit www.acell.com.

About ACell, Inc.
ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products. Its medical devices are cleared for a variety of indications and are marketed under the brand name "MatriStem." A privately held company, ACell produces MatriStem at its full scale manufacturing facilities in Columbia, MD and Lafayette, IN, and markets its products to physicians in the U.S. through a national direct sales force. For more information, call (800) 826-2926 or visit www.acell.com.

About MatriStem®
MatriStem products are porcine-derived extracellular matrix (ECM), essential structures that maintain and support a healing environment through constructive tissue remodeling. All MatriStem devices contain the basement membrane of porcine urinary bladder tissue, or urinary bladder matrix (UBM). UBM is a layer of tissue that is a critical component of constructive tissue remodeling. It provides MatriStem products with several distinguishable characteristics, including the ability to facilitate the body's own regenerative capabilities and help restore normal site-appropriate tissue while avoiding scar tissue formation; the ability to be used "off-the-shelf" and stored at room temperature, with an approximate two year shelf life; and superior ease-of-use characteristics. MatriStem products are indicated for use in a wide range of regenerative and tissue repair applications and come in a range of sizes and thicknesses. It is the only ECM of its kind available in micronized particulate form. It has been cleared for use for the reinforcement of soft tissue where weakness exists in urological, gynecological and gastroenterological anatomy, which is referred to as surgical soft tissue repair, and for the management of wounds, such as pressure ulcers, venous ulcers, diabetic ulcers, second-degree burns, surgical wounds and trauma wounds, which is referred to as complex wound management. Refer to IFU supplied with each device for indications, contraindications, and precautions. All MatriStem devices are made in the USA.

Contacts:

Cory West
Product Manager
(410) 715-1700

Kirsten Thomas (media)
The Ruth Group
(646) 536-7014
kthomas@theruthgroup.com

SOURCE ACell, Inc.

© 2014 PR Newswire
Gold & Silber auf Rekordjagd
Kaum eine Entwicklung war 2025 so eindrucksvoll wie der Höhenflug der Edelmetalle. Allen voran Silber: Angetrieben von einem strukturellen Angebotsdefizit, explodierte der Preis und übertrumpfte dabei den „großen Bruder“ Gold. Die Nachfrage aus dem Investmentsektor zieht weiter an, und ein Preisziel von 100 US-Dollar rückt in greifbare Nähe.

Auch Gold markierte neue Meilensteine. Mit dem Durchbruch über 3.000 und 4.000 US-Dollar pro Unze hat sich der übergeordnete Aufwärtstrend eindrucksvoll bestätigt. Rücksetzer bleiben möglich, doch der nächste Zielbereich bei 5.000 US-Dollar ist charttechnisch fest im Blick. Die fundamentalen Treiber sind intakt, eine nachhaltige Trendwende aktuell nicht in Sicht.

Für Anlegerinnen und Anleger bedeutet das: Jetzt ist die Zeit, um gezielt auf starke Produzenten zu setzen. In unserem neuen Spezialreport stellen wir fünf Gold- und Silberaktien vor, die trotz Rallye weiter attraktives Potenzial bieten, mit robusten Fundamentaldaten und starken Projekten in aussichtsreichen Regionen.

Jetzt den kostenlosen Report sichern und von der nächsten Welle im Edelmetall-Boom profitieren!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.